Extreme Networks, Inc. - Common Stock (EXTR)
11.62
-1.80 (-13.41%)
NASDAQ · Last Trade: Apr 3rd, 5:34 PM EDT
In a welcome move, Extreme Networks stock saw its Relative Strength Rating improve from 67 to 74 on Tuesday.
Via Investor's Business Daily · March 25, 2025

Cisco beats earnings estimates, reports strong revenue and raises guidance, leading to positive ratings and price target increases from analysts.
Via Benzinga · February 13, 2025

Via Benzinga · February 7, 2025

Look for stocks with an 80-plus RS Rating for your watch list. Extreme Networks stock just cleared that benchmark with an upgrade to 83.
Via Investor's Business Daily · December 3, 2024

Cisco's shares rise ahead of Q1 earnings release. JPMorgan analyst upgrades rating and price target, citing recovery in Networking market and refocus on Security.
Via Benzinga · November 11, 2024

Via Benzinga · November 6, 2024

The Relative Strength (RS) Rating for Extreme Networks stock climbed into a new percentile Monday, as it got a lift from 66 to 76.
Via Investor's Business Daily · November 4, 2024

Extreme Networks' recent quarterly report suggests the business may be stabilizing.
Via The Motley Fool · October 30, 2024

Via Benzinga · October 30, 2024

Via Benzinga · October 30, 2024

Via Benzinga · October 10, 2024

Via Benzinga · September 10, 2024

Weak global economic conditions, soft demand from telco and cable customers, and volatile supply chain dynamics continue to be concerns for the networking industry. Despite this, here are some stocks in the space to keep an eye on.
Via Talk Markets · June 30, 2024

Via Benzinga · June 19, 2024

Via Benzinga · June 18, 2024

Dow Jones closes 0.1% lower; S&P 500 & Nasdaq 100 fall 0.2%; Mixed data on inflation, jobless claims and housing.
Via Benzinga · May 16, 2024

Via Benzinga · May 16, 2024

Via Benzinga · May 16, 2024

EXTR stock results show that Extreme Networks missed analyst estimates for earnings per share but beat on revenue for the third quarter of 2024.
Via InvestorPlace · May 1, 2024

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic disorder causing developmental disabilities and nerve-related symptoms.
Via Benzinga · April 15, 2024

U.S. stocks were higher, with the Dow Jones index gaining over 100 points on Monday. Shares of M&T Bank Corporation (NYSE: MTB) rose sharply during Monday’s session after the company reported first-quarter financial results.
Via Benzinga · April 15, 2024